Nanobiotix Stock Performance
| NBTX Stock | USD 5.80 0.71 13.95% |
Nanobiotix holds a performance score of 20 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.15, which conveys a somewhat significant risk relative to the market. Nanobiotix returns are very sensitive to returns on the market. As the market goes up or down, Nanobiotix is expected to follow. Use Nanobiotix value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Nanobiotix.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Nanobiotix are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Nanobiotix showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 75.3 M | |
| Total Cashflows From Investing Activities | -955 K |
Nanobiotix | Build AI portfolio with Nanobiotix Stock |
Nanobiotix Relative Risk vs. Return Landscape
If you would invest 315.00 in Nanobiotix on April 25, 2025 and sell it today you would earn a total of 335.00 from holding Nanobiotix or generate 106.35% return on investment over 90 days. Nanobiotix is currently generating 1.2988% in daily expected returns and assumes 5.0991% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Nanobiotix, and 74% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nanobiotix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nanobiotix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nanobiotix, and traders can use it to determine the average amount a Nanobiotix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2547
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NBTX | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.1 actual daily | 45 55% of assets are more volatile |
Expected Return
| 1.3 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.25 actual daily | 20 80% of assets perform better |
Based on monthly moving average Nanobiotix is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nanobiotix by adding it to a well-diversified portfolio.
Nanobiotix Fundamentals Growth
Nanobiotix Stock prices reflect investors' perceptions of the future prospects and financial health of Nanobiotix, and Nanobiotix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nanobiotix Stock performance.
| Return On Equity | -1.99 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | 2.71 % | ||||
| Current Valuation | 238.35 M | ||||
| Shares Outstanding | 47.4 M | ||||
| Price To Book | 65.02 X | ||||
| Price To Sales | 3.82 X | ||||
| Revenue | (11.61 M) | ||||
| EBITDA | (58.32 M) | ||||
| Cash And Equivalents | 63.02 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 50.9 M | ||||
| Book Value Per Share | (1.39) X | ||||
| Cash Flow From Operations | (19.55 M) | ||||
| Earnings Per Share | (1.67) X | ||||
| Total Asset | 67.42 M | ||||
| Retained Earnings | (68.13 M) | ||||
About Nanobiotix Performance
Evaluating Nanobiotix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Nanobiotix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nanobiotix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company was incorporated in 2003 and is headquartered in Paris, France. Nanobiotix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people.Things to note about Nanobiotix performance evaluation
Checking the ongoing alerts about Nanobiotix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nanobiotix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nanobiotix is way too risky over 90 days horizon | |
| Nanobiotix appears to be risky and price may revert if volatility continues | |
| Nanobiotix has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68.13 M) with loss before overhead, payroll, taxes, and interest of (7.19 M). | |
| Nanobiotix currently holds about 63.02 M in cash with (19.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81. |
- Analyzing Nanobiotix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nanobiotix's stock is overvalued or undervalued compared to its peers.
- Examining Nanobiotix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nanobiotix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nanobiotix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nanobiotix's stock. These opinions can provide insight into Nanobiotix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nanobiotix Stock Analysis
When running Nanobiotix's price analysis, check to measure Nanobiotix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobiotix is operating at the current time. Most of Nanobiotix's value examination focuses on studying past and present price action to predict the probability of Nanobiotix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobiotix's price. Additionally, you may evaluate how the addition of Nanobiotix to your portfolios can decrease your overall portfolio volatility.